Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT03851497 Recruiting - Breast Cancer Clinical Trials

Application of Deep-learning and Ultrasound Elastography in Opportunistic Screening of Breast Cancer

Start date: January 1, 2019
Phase:
Study type: Observational

As the most common cancer expected to occur all over the world, breast cancer still faces with the unsatisfied diagnostic accuracy in US imaging. S-detect is a sophisticated CAD system for breast US imaging based on deep learning algorithms. E-breast is a software installed in US machines which automatically reveals tumor elastographic features. This multi-center study intends to further validate the diagnostic efficiency of S-detect and E-breast in opportunistic breast cancer screening populations in China. Our hypothesis is that S-detect and E-breast can increase the diagnostic accuracy and specificity as compared to routinely US examinations by doctors.

NCT ID: NCT03849573 Not yet recruiting - Breast Cancer Clinical Trials

A Web-Based Tool to Improve Breast Cancer Survivorship

Start date: March 20, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the efficacy of a psychosocial eHealth intervention on the proposed primary outcomes, hormone therapy adherence and health related quality of life (HRQoL), in breast cancer survivors. The intervention components include mindfulness-based stress reduction, breast cancer knowledge, stress awareness and management, social support, and enhanced communication. The intervention will be delivered via an online application over an 8-week period. Participants are randomized into either an intervention application (described above) or a control application (health information and general health promotion strategies). Aside from having access to the online application for the recommended 8 weeks with weekly online focus groups, participation in this study includes four assessments: baseline (at the beginning of the research study), post-intervention (8 weeks after baseline), a 6-month follow-up and a 12-month follow-up.

NCT ID: NCT03847623 Active, not recruiting - Breast Cancer Clinical Trials

Effect of Preoperative Curcumin in Breast Cancer Patients

EPC
Start date: June 18, 2017
Phase: N/A
Study type: Interventional

Effect of curcumin on modulation of immune and inflammatory parameters in pre-operative patients

NCT ID: NCT03847311 Not yet recruiting - Breast Cancer Clinical Trials

Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients

Start date: July 15, 2019
Phase: Early Phase 1
Study type: Interventional

Cancer in general, and breast cancer in specific, is a significant health problem in the USA and the rest of the world. With the improvement of new surgical approaches and chemotherapies to treat manage breast cancer, the number of patients with breast cancer are now living longer. This great achievement created an unexpected problem. For some breast cancer patients, pain is worse than the cancer itself. The golden standard to manage pain is opioids. These patients now are taking increasing doses of opioids to control their pain. Sadly, opioids come with significant side effects. These side effects limit the amount of opioids that can be safely administered. Many attempts have been tried to create better regiments for pain control to lower the need for opioids. There has not been significant success in that area. A better approach would be to add a non-opioid agent that has dual mechanisms of actions. This may create synergism to better control pain while lowering the doses of opioids needed and lowering side effects. Sulfasalazine poses such quality it is a safe anti-inflammatory drug with established safety profile. It has been in use for over 50 years for the treatment of inflammatory conditions such as arthritis. In addition to its anti-inflammatory characteristics, sulfasalazine has the capacity to decrease the survival of cancer cells, also to lower the amount of inflammatory mediators released by cancer cells. In short, sulfasalazine inhibit the influx of cysteine into cancer cells and the efflux of glutamate. Cysteine is needed for cell survival against oxidative stress, while glutamate activate pain receptors. Therefore, sulfasalazine will act as anti-inflammatory, an agent to accelerate cancer cells death and decreasing the released glutamate which activate pain receptors. This one agent with 3 mechanisms of actions may lower the amount of opioid needed for cancer patients while maintaining or improving their pain control. Lowering of opioid dosing may also improve the side effects associated with opioid use. The purpose of this clinical trial is to co-administer sulfasalazine with opioids to cancer patients and characterize their pain and the opioid use. Our hypothesis is that adding sulfasalazine to the pain medication, will lower the amount of opioids used and lower the side effects. This may improve the quality of life for patients and decrease the risks of using high amount of opioids for the patients, their families, and society in general.

NCT ID: NCT03847168 Not yet recruiting - Breast Cancer Clinical Trials

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Start date: April 1, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation. There are 3 proposed dose levels which are 10, 15, and 20 mg/kg, but dosing interval may be adjusted during the study (such as QW, OR Q2W, OR Q3W) based on emerging data from this trial and/or from phase 1 trial of KN026 in other country. Dose escalation will continue until the maximum tolerated dose (MTD) is reached or if MTD is not found, dose escalation will continue until the MAD of 20 mg / kg is reached.

NCT ID: NCT03846999 Completed - Breast Cancer Clinical Trials

Comorbidities and Health Care Services Utilisation Among Long-term Breast Cancer Survivors

SURBCAN
Start date: January 1, 2012
Phase:
Study type: Observational

The increased likelihood of survival can be explained by numerous factors, such as improvements in breast cancer screening and advances in diagnosis and treatment and aging. This phenomenon is associated with comorbidity due to cancer treatment and external factors like aging or lifestyle. Little is known about how these women follow-up their disease, their pattern of use of health resources and their met and unmet needs. Studying the health needs of these women is a cancer-related priority for Cancer Organizations.The project is aimed at: 1) Describing the comorbidities and patterns of use of primary and specialized care in women who have survived a breast cancer for at least five years; 2) Comparing the comorbidities and patterns of use of long time breast cancer survivors with women without a cancer diagnosis; and 3) Estimating the use of resources in long time survivors of breast cancer adjusted for survival-time and comorbidities.

NCT ID: NCT03846583 Not yet recruiting - Breast Cancer Clinical Trials

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Start date: February 28, 2019
Phase: Phase 1
Study type: Interventional

This research study is studying a combination of drugs as a possible treatment for HER2-Postive Metastatic Breast Cancer. The interventions involved in this study are: - Tucatinib - Abemaciclib (VerzenioTM) - Trastuzumab (Herceptin®) - Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)

NCT ID: NCT03846167 Not yet recruiting - Breast Cancer Clinical Trials

Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT

FTT 2
Start date: February 2019
Phase:
Study type: Observational

Patients with known or suspected, in the opinion of an investigator, primary or metastatic breast cancer may be eligible for this study. Up to 30 evaluable patients will undergo study imaging in this protocol. The imaging procedure may include one or both of the following imaging sessions; 1) a 45- 60 minute dynamic scan, starting at approximately the same time as the injection and/or 2) a skull base to mid-thigh scan starting approximately 60 minutes post injection of [18F]FTT. The planned scanning protocol will be selected by an investigator and will be discussed with the subject prior to the imaging visit. The PET/CT scan will include an injection of [18F]FTT. Data will be collected to evaluate uptake of [18F]FTT in breast cancer and compare with PARP-1 activity in tissue, when available. If patients are getting neoadjuvant or other systemic therapy, a second optional scan may be performed 1 day to 3 weeks after therapy begins to evaluate whether response correlates with increase in PARP-1 activity.response correlates with increase in PARP-1 activity.

NCT ID: NCT03845907 Recruiting - Breast Cancer Clinical Trials

Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications

Start date: December 19, 2018
Phase: N/A
Study type: Interventional

Comparative Evaluation of Gen1B (OA-16-1S) duplex OA/US probe versus Gen1 (OA-16-1) duplex OA/US probe in Healthy Subjects

NCT ID: NCT03844685 Completed - Breast Cancer Clinical Trials

Red Clover and Lifestyle Changes to Contrast Menopausal Symptoms in Premenopausal Breast Cancer Patients Given Tamoxifen

Start date: July 5, 2012
Phase: Phase 2
Study type: Interventional

A prospective double-blind randomized trial of red clover extract (Promensil) vs placebo in surgically-treated premenopausal women with estrogen receptor-positive breast cancer taking tamoxifen